image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing. 

EP2 receptor

Family: Prostanoid receptors

Contents:
Gene and Protein Information
Previous and Unofficial Names
Database Links
Agonists
Antagonists
Allosteric Regulators
Transduction Mechanisms
Tissue Distribution
Expression Datasets
Functional Assays
Physiological Functions
Physiological Consequences of Altering Gene Expression
Phenotypes, Alleles and Disease Models
Biologically Significant Variants
General Comments
References
Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 358 14q22.1 PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 61
Mouse 7 362 14 B Ptger2 prostaglandin E receptor 2 (subtype EP2) 37
Rat 7 357 15p14 Ptger2 prostaglandin E receptor 2 (subtype EP2) 15,52
Previous and Unofficial Names
prostaglandin E
prostaglandin E receptor 2 (subtype EP2), 53kD
Ptger-ep2
PGE receptor EP2 subtype
PGE receptor, EP2 subtype
PGE2 receptor EP2 subtype
prostaglandin E receptor 2
prostaglandin E receptor 2 (subtype EP2)
prostaglandin E receptor EP2 subtype
prostaglandin E2 receptor EP2 subtype
prostaglandin E2 receptor EP2 subtype-like
prostaglandin E2 receptor type 2
prostanoid EP2 receptor
Ptgerep2
Database Links
ChEMBL Target 142 (Hs), 10614 (Mm), 100427 (Rn)
DrugBank Target 406 (Hs)
Ensembl ENSG00000125384 (Hs), ENSMUSG00000037759 (Mm), ENSRNOG00000034156 (Rn), ENSRNOG00000029502 (Rn)
Entrez Gene 5732 (Hs), 19217 (Mm), 81752 (Rn)
GeneCards PTGER2 (Hs)
GenitoUrinary Development Molecular Anatomy Project Ptger2 (Mm)
HomoloGene 739 (Hs)
Human Protein Reference Database 08905 (Hs)
InterPro P43116 (Hs), Q62053 (Mm), Q62928 (Rn)
KEGG Gene hsa:5732 (Hs), mmu:19217 (Mm), rno:81752 (Rn)
OMIM 176804 (Hs)
PharmGKB Gene PA287 (Hs)
PhosphoSitePlus P43116 (Hs), Q62053 (Mm), Q62928 (Rn)
Protein Ontology (PRO) PRO:000001658 (Hs)
RefSeq Nucleotide NM_000956 (Hs), NM_008964 (Mm), NM_031088 (Rn)
RefSeq Protein NP_000947 (Hs), NP_032990 (Mm), NP_112350 (Rn)
TreeFam ENSG00000125384 (Hs), ENSMUSG00000037759 (Mm), ENSRNOG00000034156 (Rn), ENSRNOG00000029502 (Rn)
UniGene Hs. 2090 (Hs)
UniProt P43116 (Hs), Q62053 (Mm), Q62928 (Rn)
Wikipedia EP2 receptor
Prostanoid receptors
Search for 3D structures on the PDB
Search by keyword: Prostanoid receptors EP2 receptor Search by accession number: Q62928, P43116, Q62053
Natural/Endogenous Ligand(s)
PGD2
PGE2
PGF2α
PGI2
Comments: PGE2 is the principal endogenous agonist
Rank order of potency
PGE2 > PGF2α, PGI2 > PGD2, thromboxane A2
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]PGE2 Rn Full agonist 7.8 – 8.3 pKd 15,52
[3H]PGE2 Hs Full agonist 7.7 – 7.9 pKd 1,84
[3H]PGE2 Mm Full agonist 7.7 pKd 76
ONO-AE1-259 Mm Full agonist 8.5 pKi 79
PGE2 Rn Full agonist 8.2 pKi 15
PGE1 Rn Full agonist 8.0 pKi 15
PGE1 Mm Full agonist 8.0 pKi 40
PGE2 Hs Full agonist 7.5 – 8.3 pKi 1,72,84
16,16-dimethyl-PGE2 Mm Full agonist 7.8 pKi 40
PGE2 Mm Full agonist 7.4 – 7.9 pKi 40,75,79
11-deoxy-PGE1 Rn Full agonist 7.5 pKi 15
misoprostol (free acid form) Hs Full agonist 7.5 pKi 1
11-deoxy-PGE1 Mm Full agonist 7.3 pKi 40
butaprost (free acid form) Rn Full agonist 7.2 pKi 15
19(R)-OH-PGE2 Rn Full agonist 6.8 pKi 15
AH13205 Mm Full agonist 6.6 pKi 40
butaprost (free acid form) Hs Full agonist 5.9 – 7.0 pKi 1,72
ONO-4819 Mm Full agonist 6.2 pKi 90
17-phenyl-ω-trinor-PGE2 Rn Full agonist 6.1 pKi 15
AH13205 Hs Full agonist 6.0 pKi 72
carbacyclin Hs Full agonist 6.0 pKi 1
isocarbacyclin Mm Full agonist 6.0 pKi 40
19(R)-OH-PGE2 Hs Full agonist 5.9 pKi 61
cicaprost Mm Full agonist 5.9 pKi 40
iloprost Rn Full agonist 5.9 pKi 15
M&B 28767 Rn Full agonist 5.9 pKi 15
carbacyclin Mm Full agonist 5.8 pKi 40
iloprost Mm Full agonist 5.8 pKi 40
iloprost Hs Full agonist 5.7 pKi 1
ONO-AE1-329 Mm Full agonist 5.7 pKi 79
M&B 28767 Hs Full agonist 5.3 – 6.0 pKi 1,72
PGF2α Rn Full agonist 5.6 pKi 15
PGF2α Hs Full agonist 5.2 – 6.0 pKi 1,72
ONO-AE-248 Mm Full agonist 5.4 pKi 79
PGD2 Rn Full agonist 5.3 pKi 15
U46619 Rn Full agonist 5.1 pKi 15
misoprostol (methyl ester) Hs Full agonist 5.0 pKi 1
PGD2 Hs Full agonist 5.0 pKi 72
U46619 Hs Full agonist 4.9 pKi 1
CP-533536 Rn Full agonist 9.5 pEC50 17
CP-544326 Rn Full agonist 8.3 pIC50 59
CP-544326 Hs Full agonist 8.0 pIC50 59
CP-533536 Rn Full agonist 7.3 pIC50 17
View species-specific agonist tables
Agonist Comments
ONO-AE1-259 is the agonist of choice for selectively activating the EP2 receptor.

Butaprost and misoprostol may require enzymatic hydolysis of their ester moiety to achieve full bioactivity.

CP-533536 is a non prostanoid EP2 receptor agonist.

CP-544336 is the biologically-active metabolite of PF-04217329 (Taprenepag isopropyl) [59].

Another non-prostanoid EP2 agonist, o-(o-benzyloxy)-cinnamyl)-cinnamic acid [11], has very slow onset/offset of action on isolated tissue preparations, apparently due to its high lipophilicity [34].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
PF-04418948 Hs Antagonist 8.74 pA2 2
TG4-155 Hs Antagonist 8.62 pKB 32
PF-04418948 Mm Antagonist 8.32 pKB 13
AH6809 Mm Antagonist 6.5 pKi 40
AH6809 Rn Antagonist 6.3 pKi 15
AH6809 Hs Antagonist 5.9 pKi 1
View species-specific antagonist tables
Antagonist Comments
The weak, non-selective EP2 receptor antagonist, AH-6809, has been superceded by PF-04418948. Currently, PF-04418948 is the antagonist of choice for defining EP2 receptor-mediated responses.
PF-04418948 has a lower affinity (pKB = 6.95) for the guinea-pig EP2 receptor compared to the human and murine orthologues [13].
TG4-155 also has high affinity for the DP1 receptor [31-32].
Allosteric Regulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
compound 1 (Jiang et al, 2010) Hs Positive - - 33
Allosteric Regulator Comments
Compound 1 (Jiang et al, 2010, and related thiophene carboxylates) is inactive at the human EP2 receptor at concentrations up to 100uM but potentiates conventional agonist-induced responses. This effect is described by a 4- to 5-fold left-shift of PGE2 and butaprost concentration-response curves [33].

Explore drug-target interactions for this set of compounds using iPHACE

Primary Transduction Mechanisms
Transducer Effector/Response
Gs family Adenylate cyclase stimulation
References:  68,75
Tissue Distribution
Kidney: media of arteries, media of arterioles.
Species:  Human
Technique:  Immunohistochemistry.
References:  50
Eye: sclera.
Species:  Human
Technique:  Immunocytochemistry and RT-PCR.
References:  4
Myometrial cells.
Species:  Human
Technique:  Immunocytochemistry.
References:  51
Eosinophils.
Species:  Human
Technique:  Immunocytochemistry.
References:  73
Monocyte-derived dendritic cells.
Species:  Human
Technique:  RT-PCR.
References:  42
Aorta.
Species:  Human
Technique:  RT-PCR.
References:  10
Articular cartilage.
Species:  Human
Technique:  RT-PCR and Immunohistochemistry.
References:  5
Penis: corpus cavernosum.
Species:  Human
Technique:  RT-PCR and Immunohistochemistry.
References:  41
Mouth: gingival fibroblasts.
Species:  Human
Technique:  RT-PCR.
References:  53
Eye: corneal epithelium and choriocapillaries.
Species:  Human
Technique:  Immunohistochemistry.
References:  67
Airway smooth muscle cells.
Species:  Human
Technique:  RT-PCR, immunocytochemistry.
References:  19
Airway epithelial cells.
Species:  Human
Technique:  RT-PCR.
References:  25
Peritoneal neutrophils.
Species:  Mouse
Technique:  Northern blot.
References:  87
Proximal caput epididymidis.
Species:  Rat
Technique:  RT-PCR and Northern Blotting.
References:  28
Spinal cord.
Species:  Rat
Technique:  RT-PCR.
References:  38
Forebrain: meninges, ependymal layer of the lateral ventricle, hippocampus (dentate gyrus, CA1-3), lateral septal nucleus, subfornical organ, piriform cortex, bed nuclei stria terminalis, amygdala, hypothalamus (periventricular zone, ventromedial nucleus), thalamus.
Brainstem: locus coeruleus, area postrema.
Cerebellum: Purkinje cell layers.
Species:  Rat
Technique:  in situ hybridisation.
References:  92
Expression Datasets

Click here to show/hide data

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in non-pigmented epithelial (NPE) cells endogenously expressing the EP2 receptor.
Species:  Human
Tissue:  Non-pigmented epithelial (NPE) cells.
Response measured:  Stimulation of cAMP accumulation.
References:  35
Measurement of cAMP levels in COS-7 cells transfected with the human EP2 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Stimulation of cAMP accumulation.
References:  61
Measurement of cAMP levels in COS-7 cells transfected with the rat EP2 receptor.
Species:  Rat
Tissue:  COS-7 cells.
Response measured:  Stimulation of cAMP accumulation.
References:  52
Measurement of cAMP levels in CHO cells transfected with the human EP2 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of cAMP accumulation.
References:  56,85
Measurement of neuronal excitability in rat spinal cord slices endogenously expressing the EP2 receptor.
Species:  Rat
Tissue:  Spinal cord slices.
Response measured:  Depolarisation of neurons.
References:  9
Measurement of Cl- current in rat osteoclasts endogenously expressing the EP2 receptor.
Species:  Rat
Tissue:  Osteoclasts.
Response measured:  Stimulation of Cl- current.
References:  57
Measurement of T-cell factor (Tcf)/lymphoid enhancer factor (Lef) signalling in HEK 293 cells transfected with the human EP2 receptor using a Tcf/Lef-responsive luciferase reporter gene. In addition, measurement of the phosphorylation of glycogen synthase kinase-3 (GSK-3) and Akt kinase.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Activation of Tcf/Lef signalling via a PKA-dependent pathway, phosphorylation of GSK-3 and Akt kinase.
References:  23
Measurement of cAMP formation in cells over-expressing the EP2 receptor.
Species:  Human
Tissue:  C6 glioma cells.
Response measured:  Reduction in TR-FRET signal (Cisbio Bioassay).
References:  32
Physiological Functions
Bone formation.
Species:  Rat
Tissue:  In vivo.
References:  43,58
Apoptotic cell death.
Species:  Rat
Tissue:  Cortical cells.
References:  81
Relaxation of bronchial smooth muscle.
Species:  Human
Tissue:  Bronchial preparations.
References:  54
Bronchodilation.
Species:  Mouse
Tissue:  In vivo.
References:  22,70,83
Dilation of arterioles and venules.
Species:  Rat
Tissue:  Stomach.
References:  55
Blood pressure regulation (male and female).
Species:  Mouse
Tissue:  In vivo.
References:  8
Stimulation of renin release and renal vasodilation.
Species:  Mouse
Tissue:  In vivo.
References:  69
Downregulation of protease-activated receptors (PARs).
Species:  Human
Tissue:  Lung fibroblasts.
References:  71
Mediation of spinal inflammatory hyperalgesia.
Species:  Mouse
Tissue:  In vivo.
References:  62
Smooth muscle relaxation.
Species:  Rat
Tissue:  Pulmonary artery rings.
References:  24
Inhibition of sleep.
Species:  Rat
Tissue:  In vivo.
References:  91
Stimulation of calcitonin-gene related peptide (CGRP) release.
Species:  Rat
Tissue:  Primary cultures of trigeminal neurons.
References:  30
Stimulation of cell differentiation (simultaneously with EP4).
Species:  Rat
Tissue:  Primary chondrocytes.
References:  48
Reduction in osteoclast motility.
Species:  Rat
Tissue:  Osteoclasts.
References:  57
Inhibition of phagocytosis.
Species:  Rat
Tissue:  Alveolar macrophages.
References:  6
Apoptotic cell death.
Species:  Rat
Tissue:  Hippocampal cells.
References:  80
Promotion of cell growth.
Species:  Human
Tissue:  Articular chondrocytes.
References:  5
Follicle growth.
Species:  Rat
Tissue:  In vivo (ovary).
References:  20
Cumulus cell expansion in ovarian follicles.
Species:  Mouse
Tissue:  In vivo.
References:  27
Neuroprotection.
Species:  Rat
Tissue:  Hippocampal slices.
References:  47
Inhibition of TNFα formation.
Species:  Mouse
Tissue:  Kupffer cells.
References:  21
Carcinogenesis.
Species:  Human
Tissue:  Prostate cancer cell lines.
References:  31
Suppression of GM-CSF release.
Species:  Human
Tissue:  Airway smooth muscle cells.
References:  18
Relaxation.
Species:  Mouse
Tissue:  Tracheal smooth muscle.
References:  13
Inhibition of TNFα release.
Species:  Human
Tissue:  Alveolar macrophages.
References:  60
Reduction of intraocular pressure.
Species:  Human
Tissue:  Eye.
References:  66
Augementation of G-CSF secretion.
Species:  Human
Tissue:  Airway smooth muscle cells.
References:  19
Inhibition of migration.
Species:  Human
Tissue:  Airway smooth muscle cells.
References:  7
Physiological Consequences of Altering Gene Expression
Mediation of immune suppression in cancer.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  89
EP2 receptor knockout mice exhibit a protective effect against neuronal oxidative damage.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  49
EP2 receptor knockout mice do not exhibit the bronchodilatory response to PGE2 seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  22,70,83
EP2 receptor knockout mice exhibit salt-sensitive hypertension in response to PGE2 and reduced fertility.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  39,82
EP2 receptor knockout mice exhibit reduced PGE2-induced vasodepression compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  8
EP2 receptor knockout mice exhibit PGE2-mediated renal vasoconstriction, in contrast to the vasodilation seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  29
EP2 receptor knockout mice exhibit an increase in mean arterial pressure, in contrast to a decrease in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  93
EP2 receptor knockout mice do not exhibit spinal PGE2-evoked hyperalgesia, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  62
EP2 receptor knockout mice exhibit resistance to the inhibitory effect of PGE2 on phagocytosis by alveolar macrophages.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  6
EP2 receptor knockout mice do not exhibit complete cumulus expansion and hence display impaired fertility.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  27
Osteoblasts from EP2 receptor knockout mice have an impaired ability to stimulate osteoclast formation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  44
EP2 receptor knockout mice exhibit weak bones.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  3
EP2 receptor knockout mice exhibit an impaired hypercalcemic response to PGE2.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  45
EP2 receptor knockout mice exhibit a reduced increase in aqueous humour protein concentration in the eye and an inhibition of the disruption of the blood-aqueous barrier, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  12,14
EP2 receptor knockout mice subjected to permanent focal ischemia exhibit increased excitotoxicity compared to wild-type mice subjected to the same permanent focal ischemia.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  47
Peritoneal neutrophils from EP2 receptor knockout mice do not exhibit PGE2-mediated G-CSF (granulocyte colony-stimulating factor, a hemopoietic growth factor) release, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  74
Tracheal rings from EP2 receptor knockout mice appear to be resistant to cytokine-mediated β2-adrenoceptor desensitisation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  26
EP2 receptor knockout mice exhibit reduced keratinocyte proliferation and reduced tumour development.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  77
Transgenic mice overexpressing the EP2 receptor exhibit increased keratinocyte proliferation and increased tumour development.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  78
EP2 receptor knockout mice exhibit impaired tumour angiogenesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  36
Deletion of the EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness.
Species:  Mouse
Tissue:  Skin.
Technique:  Gene targeting in embryonic stem cells.
References:  16
A familial model of Alzheimer's disease deficient in the EP2-receptor displays a reduction in lipid peroxidation that is associated with decreases in amyloid beta peptides and amyloid deposition.
Species:  Mouse
Tissue:  Brain.
Technique:  Gene targeting in embryonic stem cells.
References:  46
EP2 receptor agonists fail to reduce intraocular pressure in PTGER2-knockout mice.
Species:  Mouse
Tissue:  Eye.
Technique:  Gene knockouts.
References:  63
EP2 receptor knockout mice have higher systolic blood pressure when compared to wild-type mice.
Species:  Mouse
Tissue:  Cardiovascular system.
Technique:  Gene targeting in embryonic stem cells.
References:  60
EP2 receptor deficiency results in impaired cognition, sensorimotor gating, and hippocampal long-term depression.
Species:  Mouse
Tissue:  Brain.
Technique:  Gene targeting in embryonic stem cells.
References:  65
EP2 receptor deficiency impairs hippocampal long-term synaptic plasticity and cognition.
Species:  Mouse
Tissue:  Brain.
Technique:  Gene targeting in embryonic stem cells.
References:  88
EP2 receptor deficiency exacerbates vascular neointimal formation.
Species:  Mouse
Tissue:  Femoral artery.
Technique:  Gene targeting in embryonic stem cells.
References:  94
Phenotypes, Alleles and Disease Models Mouse data from MGI

Click here to show/hide data

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0002334 abnormal airway responsiveness PMID: 10846038 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6)		 MGI:97794  MP:0001562 abnormal circulating calcium level PMID: 12013525 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0009373 abnormal cumulus expansion PMID: 9751056 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
C.129S6-Ptger2		 MGI:97794  MP:0002912 abnormal excitatory postsynaptic potential PMID: 19012750 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
C.129S6-Ptger2		 MGI:97794  MP:0003691 abnormal microglial cell physiology PMID: 15793296 
Ptger2tm1Brey|Tg(APPswe,PSEN1dE9)85Dbo Ptger2tm1Brey/Ptger2tm1Brey,Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6		 MGI:3525178  MGI:97794  MP:0003633 abnormal nervous system physiology PMID: 16267225 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * BALB/c		 MGI:97794  MP:0003633 abnormal nervous system physiology PMID: 12423256 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0001125 abnormal oocyte morphology PMID: 10468638 
Ptger2tm1Rsz Ptger2tm1Rsz/Ptger2tm1Rsz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0008396 abnormal osteoclast differentiation PMID: 10830290 
Ptger2tm2Bhk Ptger2tm2Bhk/Ptger2tm2Bhk
involves: 129P2/OlaHsd * 129S/SvEv		 MGI:97794  MP:0005581 abnormal renin activity PMID: 10359563 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0005025 abnormal response to infection PMID: 17330822 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * BALB/c		 MGI:97794  MP:0005025 abnormal response to infection PMID: 12423256 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
B6.129S6-Ptger2		 MGI:97794  MP:0005164 abnormal response to injury PMID: 14715958 
Hrhr|Ptger2tm1Brey Hrhr/Hrhr,Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6 * SKH1		 MGI:96223  MGI:97794  MP:0005501 abnormal skin physiology PMID: 16977324 
Hrhr|Ptger2+|Ptger2tm1Brey Hrhr/Hrhr,Ptger2tm1Brey/Ptger2+
involves: 129S6/SvEvTac * C57BL/6 * SKH1		 MGI:96223  MGI:97794  MP:0005501 abnormal skin physiology PMID: 16977324 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
B6.129S6-Ptger2		 MGI:97794  MP:0001463 abnormal spatial learning PMID: 19012750 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0009648 abnormal superovulation PMID: 11319164 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0001613 abnormal vasodilation PMID: 9930871 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac		 MGI:97794  MP:0001613 abnormal vasodilation PMID: 12167591 
Hrhr|Ptger2tm1Brey Hrhr/Hrhr,Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6 * SKH1		 MGI:96223  MGI:97794  MP:0003448 altered tumor morphology PMID: 16977324 
Ptger2tm1Brey|Tg(APPswe,PSEN1dE9)85Dbo Ptger2tm1Brey/Ptger2tm1Brey,Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6		 MGI:3525178  MGI:97794  MP:0000604 amyloidosis PMID: 16267225 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0002680 decreased corpora lutea number PMID: 10468638 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac		 MGI:97794  MP:0004502 decreased incidence of chemically-induced tumors PMID: 16886605 
Hrhr|Ptger2tm1Brey Hrhr/Hrhr,Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6 * SKH1		 MGI:96223  MGI:97794  MP:0004504 decreased incidence of UV-induced tumors PMID: 16977324 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0001935 decreased litter size PMID: 9930871 
Ptger2tm2Bhk Ptger2tm2Bhk/Ptger2tm2Bhk
involves: 129P2/OlaHsd * 129S/SvEv		 MGI:97794  MP:0001935 decreased litter size PMID: 10359563 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0001935 decreased litter size PMID: 10468638 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0003355 decreased ovulation rate PMID: 10468638 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac		 MGI:97794  MP:0003447 decreased tumor growth/size PMID: 16886605 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0009374 failure of cumulus expansion PMID: 10468638 
Ptger2tm2Bhk Ptger2tm2Bhk/Ptger2tm2Bhk
involves: 129P2/OlaHsd * 129S/SvEv		 MGI:97794  MP:0001596 hypotension PMID: 10359563 
Ptger2tm2Bhk Ptger2tm2Bhk/Ptger2tm2Bhk
involves: 129P2/OlaHsd * 129S/SvEv		 MGI:97794  MP:0000242 impaired fertilization PMID: 10359563 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0000242 impaired fertilization PMID: 10468638 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
B6.129S6-Ptger2		 MGI:97794  MP:0006060 increased cerebral infarction size PMID: 14715958 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0002842 increased systemic arterial blood pressure PMID: 9930871 
Hrhr|Ptger2tm1Brey Hrhr/Hrhr,Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6 * SKH1		 MGI:96223  MGI:97794  MP:0003721 increased tumor growth/size PMID: 16977324 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac		 MGI:97794  MP:0003025 increased vasoconstriction PMID: 12167591 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6		 MGI:97794  MP:0001923 reduced female fertility PMID: 9930871 
Ptger2tm2Bhk Ptger2tm2Bhk/Ptger2tm2Bhk
involves: 129P2/OlaHsd * 129S/SvEv		 MGI:97794  MP:0001923 reduced female fertility PMID: 10359563 
Ptger2tm1Sna Ptger2tm1Sna/Ptger2tm1Sna
involves: 129P2/OlaHsd * C57BL/6		 MGI:97794  MP:0001923 reduced female fertility PMID: 10468638 
Ptger2tm1Brey Ptger2tm1Brey/Ptger2tm1Brey
C.129S6-Ptger2		 MGI:97794  MP:0001473 reduced long term potentiation PMID: 19012750 
Biologically Significant Variants
rs17197 more frequent polymorphism in Japanese men with essential hypertension when compared to normotensive counterparts. Proposed to be a genetic marker of essential hypertension.
SNP accession:  rs17197 
Type:  Naturally occurring SNPs.
Species:  Human
References:  64
General Comments
For futher information on the properties of the EP2 receptor and its ligands, see the the NC-IUPHAR sponsored review of Woodward et al, 2011 [86].

REFERENCES

Show »

1. Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N. M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N. and Metters, K. M. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogues. Biochim. Biophys. Acta., 1483: 285-293. [PMID:10634944]

2. af Forselles, KJ; Root, J; Clarke, T; Davey, D; Aughton, K; Dack, K; Pullen, N. (2011) In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist. Br. J. Pharmacol., 164 (7): 1847-56. [PMID:21595651]

3. Akhter, M. P., Cullen, D. M., Gong, G. and Recker, R. R. (2001) Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone, 29: 121-125. [PMID:11502472]

4. Anthony, T. L., Lindsey, J. D., Aihara, M. and Weinreb, R. N. (2001) Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sclera. Invest Ophthalmol Vis Sci, 42: 3182-3186. [PMID:11726620]

5. Aoyama, T., Liang, B., Okamoto, T., Matsusaki, T., Nishijo, K., Ishibe, T., Yasura, K., Nagayama, S., Nakayama, T., Nakamura, T. and Toguchida, J. (2005) PGE2 signal through EP2 promotes the growth of articular chondrocytes. J Bone Miner Res, 20: 377-389. [PMID:15746982]

6. Aronoff, D. M., Canetti, C. and Peters-Golden, M. (2004) Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol, 173: 559-565. [PMID:15210817]

7. Aso, H; Ito, S; Mori, A; Suganuma, N; Morioka, M; Takahara, N; Kondo, M; Hasegawa, Y. (2013) Differential regulation of airway smooth muscle cell migration by e-prostanoid receptor subtypes. Am. J. Respir. Cell Mol. Biol., 48 (3): 322-9. [PMID:23221043]

8. Audoly, L. P., Tilley, S. L., Goulet, J, Key, M., Nguyen, M., Stock, J. L., McNeish, J. D., Koller, B. H. and Coffman, T. M. (1999) Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. Am. J. Physiol., 277: H924-H930. [PMID:10484412]

9. Baba, H., Kohno, T., Moore, K. A. and Woolf, C. J. (2001) Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci, 21: 1750-1756. [PMID:11222664]

10. Bayston, T; Ramessur, S; Reise, J; Jones, KG; Powell, JT. (2003) Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J. Vasc. Surg., 38 (2): 354-9. [PMID:12891120]

11. Belley, M; Gallant, M; Roy, B; Houde, K; Lachance, N; Labelle, M; Trimble, LA; Chauret, N; Li, C; Sawyer, N; et al.. (2005) Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists. Bioorg. Med. Chem. Lett., 15 (3): 527-30. [PMID:15664806]

12. Bhattacherjee, P., Mukhopadhyay, P., Tilley, S. L., Koller, B. H., Geoghgan, T. and Paterson, C. A. (2002) Blood-aqueous barrier in prostaglandin EP2 receptor knockout mice. Ocul Immunol Inflamm, 10: 187-196. [PMID:12789594]

13. Birrell, MA; Maher, SA; Buckley, J; Dale, N; Bonvini, S; Raemdonck, K; Pullen, N; Giembycz, MA; Belvisi, MG. (2013) Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br. J. Pharmacol., 168 (1): 129-38. [PMID:22747912]

14. Biswas, S., Bhattacherjee, P., Paterson, C. A., Tilley, S. L. and Koller, B. H. (2006) Ocular inflammatory responses in the EP2 and EP4 receptor knockout mice. Ocul Immunol Inflamm, 14: 157-163. [PMID:16766399]

15. Boie, Y., Stocco, R., Sawyer, N., Slipetz, D. M., Ungrin, M. D., Neuschafer-Rube, F., Puschel, G. P., Metters, K. M. and Abramovitz, M. (1997) Molecular cloning and characterisation of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur. J. Pharmacol., 304: 227-241. [PMID:9537820]

16. Brouxhon, S; Konger, RL; VanBuskirk, J; Sheu, TJ; Ryan, J; Erdle, B; Almudevar, A; Breyer, RM; Scott, G; Pentland, AP. (2007) Deletion of prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, but increases tumor aggressiveness. J. Invest. Dermatol., 127 (2): 439-46. [PMID:16977324]

17. Cameron, KO; Lefker, BA; Ke, HZ; Li, M; Zawistoski, MP; Tjoa, CM; Wright, AS; DeNinno, SL; Paralkar, VM; Owen, TA; et al.. (2009) Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg. Med. Chem. Lett., 19 (7): 2075-8. [PMID:19250823]

18. Clarke, DL; Belvisi, MG; Catley, MC; Yacoub, MH; Newton, R; Giembycz, MA. (2004) Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM-CSF. Br. J. Pharmacol., 141 (7): 1141-50. [PMID:15023863]

19. Clarke, DL; Belvisi, MG; Smith, SJ; Hardaker, E; Yacoub, MH; Meja, KK; Newton, R; Slater, DM; Giembycz, MA. (2005) Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor. Am. J. Physiol. Lung Cell Mol. Physiol., 288 (2): L238-50. [PMID:15640521]

20. El-Nefiawy, N., Abdel-Hakim, K., Kanayama, N. and Terao, T. (2005) Role of prostaglandin E2 receptor subtypes in ovarian follicle growth in the rat in vivo. Correlation with interleukin-8 and neutrophils. Histol Histopathol, 20: 825-831. [PMID:15944932]

21. Fennekohl, A., Sugimoto, Y., Segi, E., Maruyama, T., Ichikawa, A. and Püschel, G. P. (2002) Contribution of the two Gs-coupled PGE2-receptors EP2-receptor and EP4-receptor to the inhibition by PGE2 of the LPS-induced TNFalpha-formation in Kupffer cells from EP2-or EP4-receptor-deficient mice. Pivotal role for the EP4-receptor in wild type Kupffer cells. J Hepatol, 36: 328-334. [PMID:11867175]

22. Fortner, C. N., Breyer, R. M. and Paul, R. J. (2001) EP2 receptors mediate airway relaxation to substance P, ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol, 281: L469-L474. [PMID:11435222]

23. Fujino, H., West, K. A. and Regan, J. W. (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem, 277: 2614-2619. [PMID:11706038]

24. Fullerton, D. A., Agrafojo, J. and McIntyre, R. C. (1996) Pulmonary vascular smooth muscle relaxation by cAMP-mediated pathways. J Surg Res, 61: 444-448. [PMID:8656622]

25. Gray, T; Nettesheim, P; Loftin, C; Koo, JS; Bonner, J; Peddada, S; Langenbach, R. (2004) Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol. Pharmacol., 66 (2): 337-46. [PMID:15266025]

26. Guo, M., Pascual, R. M., Wang, S., Fontana, M. F., Valancius, C. A., Panettieri, R. A., Tilley, S. L. and Penn, R. B. (2005) Cytokines regulate beta-2-adrenergic receptor responsiveness in airway smooth muscle via multiple PKA- and EP2 receptor-dependent mechanisms. Biochemistry, 44: 13771-13782. [PMID:16229467]

27. Hizaki, H., Segi, E., Sugimoto, Y., Hirose, M., Saji, T., Ushikubi, F., Matsuoka, T., Noda, Y., Tanaka, T., Yoshida, N., Narumiya, S. and Ichikawa, A. (2000) Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. Proc. Natl. Acad. Sci. U.S.A., 96: 10501-10506. [PMID:10468638]

28. Ibrahim, N. M., Young, L. G. and Fröhlich, O. (2001) Epididymal specificity and androgen regulation of rat EP2. Biol Reprod, 65: 575-580. [PMID:11466228]

29. Imig, J. D., Breyer, M. D. and Breyer, R. M. (2002) Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol, 283: F415-F422. [PMID:12167591]

30. Jenkins, D. W., Feniuk, W. and Humphrey, P. P. (2001) Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol, 134: 1296-1302. [PMID:11704650]

31. Jiang, J; Dingledine, R. (2013) Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J. Pharmacol. Exp. Ther., 344 (2): 360-7. [PMID:23192657]

32. Jiang, J; Ganesh, T; Du, Y; Quan, Y; Serrano, G; Qui, M; Speigel, I; Rojas, A; Lelutiu, N; Dingledine, R. (2012) Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc. Natl. Acad. Sci. U.S.A., 109 (8): 3149-54. [PMID:22323596]

33. Jiang, J; Ganesh, T; Du, Y; Thepchatri, P; Rojas, A; Lewis, I; Kurtkaya, S; Li, L; Qui, M; Serrano, G; et al.. (2010) Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc. Natl. Acad. Sci. U.S.A., 107 (5): 2307-12. [PMID:20080612]

34. Jones, RL; Wan Ahmad, WA; Woodward, DF; Wang, J. (2013) Nature of the slow relaxation of smooth muscle induced by a EP(2) receptor agonist with a non-prostanoid structure. Prostaglandins Leukot. Essent. Fatty Acids,  [Epub ahead of print]. [PMID:23419768]

35. Jumblatt, M. M., Neltner, A. A., Coca-Prados, M. and Paterson, C. A. (1994) EP2-receptor stimulated cyclic AMP synthesis in cultured human non-pigmented ciliary epithelium. Exp Eye Res, 58: 563-566. [PMID:7925693]

36. Kamiyama, M., Pozzi, A., Yang, L., Debusk, L. M., Breyer, R. M. and Lin, P. C. (2006) EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene, : -. [PMID:16732324]

37. Katsuyama, M., Nishigaki, N., Sugimoto, Y., Morimoto, K., Negishi, M., Narumiya, S. and Ichikawa, A. (1995) The mouse prostaglandin E receptor EP2 subtype, cloning, expression and northern blot analysis. FEBS Lett., 372: 151-156. [PMID:7556658]

38. Kawamura, T., Yamauchi, T., Koyama, M., Maruyama, T., Akira, T. and Nakamura, N. (1997) Expression of prostaglandin EP2 receptor mRNA in the rat spinal cord. Life Sci, 61: 2111-2116. [PMID:9395252]

39. Kennedy, C. R. J., Zhang, Y., Brandon, S., Guan, Y., Coffee, K., Funk, C. D., Magnuson, M. A., Oates, J. A., Breyer, M. D. and Breyer, R. M. (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med., 5: 217-220. [PMID:9930871]

40. Kiriyama, M., Ushikubi, F., Kobayashi, T., Hirata, M., Sugimoto, Y. and Narumiya, S. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol., 122: 217-224. [PMID:9313928]

41. Komuro, M., Kamiyama, M., Furuya, Y., Takihana, Y., Araki, I. and Takeda, M. (2006) Gene and protein expression profiles of prostaglandin E2 receptor subtypes in the human corpus cavernosum. Int J Impot Res, 18: 275-281. [PMID:16239896]

42. Kubo, S; Takahashi, HK; Takei, M; Iwagaki, H; Yoshino, T; Tanaka, N; Mori, S; Nishibori, M. (2004) E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. J. Pharmacol. Exp. Ther., 309 (3): 1213-20. [PMID:14872092]

43. Li, M., Ke, H. Z., Qi, H., Healy, D. R., Li, Y., Crawford, D. T., Paralkar, V. M., Owen, T. A., Cameron, K. O., Lefker, B. A., Brown, T. A. and Thompson, D. D. (2003) A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res, 18: 2033-2042. [PMID:14606517]

44. Li, X., Okada, Y., Pilbeam, C. C., Lorenzo, J. A., Kennedy, C. R., Breyer, R. M. and Raisz, L. G. (2000) Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology, 141: 2054-2061. [PMID:10830290]

45. Li, X., Tomita, M., Pilbeam, C. C., Breyer, R. M. and Raisz, L. G. (2002) Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. Prostaglandins Other Lipid Mediat, 67: 173-180. [PMID:12013525]

46. Liang, X; Wang, Q; Hand, T; Wu, L; Breyer, RM; Montine, TJ; Andreasson, K. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci., 25 (44): 10180-7. [PMID:16267225]

47. Liu, D., Wu, L., Breyer, R., Mattson, M. P. and Andreasson, K. (2005) Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol, 57: 758-761. [PMID:15852374]

48. Miyamoto, M., Ito, H., Mukai, S., Kobayashi, T., Yamamoto, H., Kobayashi, M., Maruyama, T., Akiyama, H. and Nakamura, T. (2003) Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation. Osteoarthritis Cartilage, 11: 644-652. [PMID:12954235]

49. Montine, T. J., Milatovic, D., Gupta, R. C., Valyi-Nagy, T., Morrow, J. D. and Breyer, R. M. (2002) Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem, 83: 463-470. [PMID:12423256]

50. Morath, R., Klein, T., Seyberth, H. W. and Nüsing, R. M. (1999) Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol, 10: 1851-1860. [PMID:10477136]

51. Mosher, AA; Rainey, KJ; Giembycz, MA; Wood, S; Slater, DM. (2012) Prostaglandin E2 represses interleukin 1 beta-induced inflammatory mediator output from pregnant human myometrial cells through the EP2 and EP4 receptors. Biol. Reprod., 87 (1): 7, 1-10. [PMID:22517618]

52. Nemoto, K., Pilbeam, C. C., Bilak, S. R. and Raisz, L. G. (1997) Molecular cloning and expression of a rat prostaglandin E2 receptor of the EP2 subtype. Prostaglandins, 54: 713-725. [PMID:9440134]

53. Noguchi, K., Shitashige, M., Endo, H., Kondo, H. and Ishikawa, I. (2002) Binary regulation of interleukin (IL)-6 production by EP1 and EP2/EP4 subtypes of PGE2 receptors in IL-1beta-stimulated human gingival fibroblasts. J Periodontal Res, 37: 29-36. [PMID:11842936]

54. Norel, X., Walch, L., Labat, C., Gascard, J. P., Dulmet, E. and Brink, C. (1999) Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol, 126: 867-872. [PMID:10193766]

55. Ohno, T., Katori, M., Majima, M., Saeki, T., Boku, K., Nishiyama, K., Hayashi, H. and Saigenji, K. (1999) Dilatation and constriction of rat gastric mucosal microvessels through prostaglandin EP2 and EP3 receptors. Aliment Pharmacol Ther, 13: 1243-1250. [PMID:10468708]

56. Okada, Y., Taniguchi, T., Morishima, S., Suzuki, F., Akagi, Y. and Muramatsu, I. (2006) Characteristics of acid extrusion from Chinese hamster ovary cells expressing different prostaglandin EP receptors. Life Sci, 78: 2454-2462. [PMID:16300797]

57. Okamoto, F., Kajiya, H., Fukushima, H., Jimi, E. and Okabe, K. (2004) Prostaglandin E2 activates outwardly rectifying Cl(-) channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts. Am J Physiol Cell Physiol, 287: C114-C124. [PMID:15044156]

58. Paralkar, V. M., Borovecki, F., Ke, H. Z., Cameron, K. O., Lefker, B., Grasser, W. A., Owen, T. A., Li, M., DaSilva-Jardine, P., Zhou, M., Dunn, R. L., Dumont, F., Korsmeyer, R., Krasney, P., Brown, T. A., Plowchalk, D., Vukicevic, S. and Thompson, D. D. (2003) An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A, 100: 6736-6740. [PMID:12748385]

59. Prasanna, G; Carreiro, S; Anderson, S; Gukasyan, H; Sartnurak, S; Younis, H; Gale, D; Xiang, C; Wells, P; Dinh, D; et al.. (2011) Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Exp. Eye Res., 93 (3): 256-64. [PMID:21376717]

60. Ratcliffe, MJ; Walding, A; Shelton, PA; Flaherty, A; Dougall, IG. (2007) Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. Eur. Respir. J., 29 (5): 986-94. [PMID:17331962]

61. Regan, J. W., Bailey, T. J., Pepperl, D. J., Pierce, K. L., Bogardus, A. M., Donello, J. E., Fairbairn, C. E., Kedzie, K. M., Woodward, D. F. and Gil, D. W. (1994) Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol., 40: 213-220. [PMID:8078484]

62. Reinold, H., Ahmadi, S., Depner, U. B., Layh, B., Heindl, C., Hamza, M., Pahl, A., Brune, K., Narumiya, S., Müller, U. and Zeilhofer, H. U. (2005) Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest, 115: 673-679. [PMID:15719070]

63. Saeki, T; Ota, T; Aihara, M; Araie, M. (2009) Effects of prostanoid EP agonists on mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci., 50 (5): 2201-8. [PMID:19117925]

64. Sato, M; Nakayama, T; Soma, M; Aoi, N; Kosuge, K; Haketa, A; Izumi, Y; Matsumoto, K; Sato, N; Kokubun, S. (2007) Association between prostaglandin E2 receptor gene and essential hypertension. Prostaglandins Leukot. Essent. Fatty Acids, 77 (1): 15-20. [PMID:17644362]

65. Savonenko, A; Munoz, P; Melnikova, T; Wang, Q; Liang, X; Breyer, RM; Montine, TJ; Kirkwood, A; Andreasson, K. (2009) Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp. Neurol., 217 (1): 63-73. [PMID:19416671]

66. Schachar, R.A., Raber, S., Courtney, R., Zhang, M., Bosworth, C. (2010) Dose-Escalating, Double-Masked, Vehicle-Controlled Trial of the IOP-Reducing Effect of EP2 Agonist, Taprenepag Isopropyl (PF-04217329). ARVO Poster, : #175/A398.

67. Schlötzer-Schrehardt, U., Zenkel, M. and Nüsing, R. M. (2002) Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci, 43: 1475-1487. [PMID:11980863]

68. Schwaner, I., Offermanns, S., Spicher, K., Seifert, R. and Schultz, G. (1995) Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL. Biochim Biophys Acta, 1265: 8-14. [PMID:7532011]

69. Schweda, F., Klar, J., Narumiya, S., Nüsing, R. M. and Kurtz, A. (2004) Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol, 287: F427-F433. [PMID:15113745]

70. Sheller, J. R., Mitchell, D., Meyrick, B., Oates, J. and Breyer, R. (2000) EP(2) receptor mediates bronchodilation by PGE(2) in mice. J Appl Physiol, 88: 2214-2218. [PMID:10846038]

71. Sokolova, E., Grishina, Z., Bühling, F., Welte, T. and Reiser, G. (2005) Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2. Am J Physiol Lung Cell Mol Physiol, 288: L793-L802. [PMID:15563688]

72. Stillman, B. A., Breyer, M. D. and Breyer, R. M. (1999) Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol, 56: 545-551. [PMID:10462542]

73. Sturm, EM; Schratl, P; Schuligoi, R; Konya, V; Sturm, GJ; Lippe, IT; Peskar, BA; Heinemann, A. (2008) Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J. Immunol., 181 (10): 7273-83. [PMID:18981149]

74. Sugimoto, Y., Fukada, Y., Mori, D., Tanaka, S., Yamane, H., Okuno, Y., Deai, K., Tsuchiya, S., Tsujimoto, G. and Ichikawa, A. (2005) Prostaglandin E2 stimulates granulocyte colony-stimulating factor production via the prostanoid EP2 receptor in mouse peritoneal neutrophils. J Immunol, 175: 2606-2612. [PMID:16081835]

75. Sugimoto, Y., Nakato, T., Kita, A., Hatae, N., Tabata, H., Tanaka, S. and Ichikawa, A. (2003) Functional domains essential for Gs activity in prostaglandin EP2 and EP3 receptors. Life Sci, 74: 135-141. [PMID:14607240]

76. Sugimoto, Y., Nakato, T., Kita, A., Takahashi, Y., Hatae, N., Tabata, H., Tanaka, S. and Ichikawa, A. (2004) A cluster of aromatic amino acids in the i2 loop plays a key role for Gs coupling in prostaglandin EP2 and EP3 receptors. J Biol Chem, 279: 11016-11026. [PMID:14699136]

77. Sung, Y. M., He, G. and Fischer, S. M. (2005) Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res, 65: 9304-9311. [PMID:16230392]

78. Sung, Y. M., He, G., Hwang, D. H. and Fischer, S. M. (2006) Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene, : -. [PMID:16607275]

79. Suzawa, T., Miyaura, C., Inada, M., Maruyama, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., Narumiya, S. and Suda, T. (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology, 141: 1554-1559. [PMID:10746663]

80. Takadera, T., Shiraishi, Y. and Ohyashiki, T. (2004) Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons. Neurochem Int, 45: 713-719. [PMID:15234114]

81. Takadera, T., Yumoto, H., Tozuka, Y. and Ohyashiki, T. (2002) Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. Neurosci Lett, 317: 61-64. [PMID:11755240]

82. Tilley, S. L., Audoly, L. P., Hicks, E. H., Kim, H. S., Flannery, P. J., Coffman, T. M. and Koller, B. H. (1999) Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest, 103: 1539-1545. [PMID:10359563]

83. Tilley, S. L., Hartney, J. M., Erikson, C. J., Jania, C., Nguyen, M., Stock, J., McNeisch, J., Valancius, C., Panettieri, R. A., Penn, R. B. and Koller, B. H. (2003) Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol, 284: L599-L606. [PMID:12618422]

84. Wilson, R. J., Giblin, G. M., Roomans, S., Rhodes, S. A., Cartwright, K. A., Shield, V. J., Brown, J., Wise, A., Chowdhury, J., Pritchard, S., Coote, J., Noel, L. S., Kenakin, T., Burns-Kurtis, C. L., Morrison, V., Gray, D. W. and Giles, H. (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol, 148: 326-339. [PMID:16604093]

85. Wilson, R. J., Rhodes, S. A., Wood, R. L., Shield, V. J., Noel, L. S., Gray, D. W. and Giles, H. (2004) Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur J Pharmacol, 501: 49-58. [PMID:15464062]

86. Woodward, DF; Jones, RL; Narumiya, S. (2011) International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev., 63 (3): 471-538. [PMID:21752876]

87. Yamane, H; Sugimoto, Y; Tanaka, S; Ichikawa, A. (2000) Prostaglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem. Biophys. Res. Commun., 278 (1): 224-8. [PMID:11071876]

88. Yang, H; Zhang, J; Breyer, RM; Chen, C. (2009) Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J. Neurochem., 108 (1): 295-304. [PMID:19012750]

89. Yang, L., Yamagata, N., Yadav, R., Brandon, S., Courtney, R. L., Morrow, J. D., Shyr, Y., Boothby, M., Joyce, S., Carbone, D. P. and Breyer, R. M. (2003) Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest, 111: 727-735. [PMID:12618527]

90. Yoshida, K., Oida, H., Kobayashi, T., Maruyama, T., Tanaka, M., Katayama, T., Yamaguchi, K., Segi, E., Tsuboyama, T., Matsushita, M., Ito, K., Ito, Y., Sugimoto, Y., Ushikubi, F., Ohuchida, S., Kondo, K., Nakamura, T. and Narumiya, S. (2002) Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A, 99: 4580-4585. [PMID:11917107]

91. Yoshida, Y., Matsumura, H., Nakajima, T., Mandai, M., Urakami, T., Kuroda, K. and Yoneda, H. (2000) Prostaglandin E (EP) receptor subtypes and sleep: promotion by EP4 and inhibition by EP1/EP2. Neuroreport, 11: 2127-2131. [PMID:10923657]

92. Zhang, J. and Rivest, S. (1999) Distribution, regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur J Neurosci, 11: 2651-2668. [PMID:10457163]

93. Zhang, Y., Guan, Y., Schneider, A., Brandon, S., Breyer, R. M. and Breyer, M. D. (2000) Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors. Hypertension, 35: 1129-1134. [PMID:10818076]

94. Zhu, S; Xue, R; Zhao, P; Fan, FL; Kong, X; Zheng, S; Han, Q; Zhu, Y; Wang, N; Yang, J; et al.. (2011) Targeted disruption of the prostaglandin E2 E-prostanoid 2 receptor exacerbates vascular neointimal formation in mice. Arterioscler. Thromb. Vasc. Biol., 31 (8): 1739-47. [PMID:21636806]

To cite this database page, please use the following:

Mark Giembycz, Xavier Norel, Mark Abramovitz, Richard M. Breyer, Robert A. Coleman, Rebecca Hills, Robert L. Jones, Shuh Narumiya, David F. Woodward.
Prostanoid receptors: EP2 receptor. Last modified on 13/03/2013. Accessed on 19/06/2013. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=341.


Contact us | Print | Back to top | Help